Paul-Peter Tak

From Wikipedia, the free encyclopedia

Paul Peter Tak

FMedSci
Alma materVrije Universiteit Amsterdam
Leiden University
Scientific career
FieldsImmunology, gene therapy, bioelectronics
InstitutionsCandel Therapeutics
Kintai Therapeutics
GlaxoSmithKline

Paul-Peter Tak FMedSci is an immunologist and academic specialising in the fields of rheumatology and immunology. In addition to academic research, he served as an executive of several pharmaceutical companies.

Life and career[]

Tak graduated as a doctor of medicine from the Free University of Amsterdam and began his medical career as a practitioner in the Bronovo Hospital, The Hague.[1] He joined Leiden University Medical Centre as a Fellow in Internal Medicine in 1990 and was awarded a Fellowship in Rheumatology in 1995.[2] Tak received his PhD from the University of Leiden in 1996 for his thesis Immunohistologic studies of rheumatoid synovial tissue.[1]

Tak has studied the role of the vagus nerve in chronic inflammation, work which provided the basis for clinical trials exploring bioelectronics as a novel therapeutic approach in rheumatoid arthritis patients.[3] He is also known for his studies on synovial biopsy and synovial tissue analysis.[4] In his academic life, Tak has been Visiting Professor, William Harvey Research Institute (London), Honorary Senior Visiting Fellow (University of Cambridge), Honorary Professor of Rheumatology (Ghent University) and was elected a Fellow of the Academy of Medical Sciences (U.K.) in 2016.[5]

His was elected by peers as "Best Rheumatologist" in the Netherlands in 2011,[6] and received the Medal of Honour of the Netherlands Society for Rheumatology the same year.[7] He was rated as one of the world’s top 3 doctors in the field of rheumatoid arthritis by Expertscape in 2014.[8]

Tak was chief executive at Tempero Pharmaceutical, which was acquired by GlaxoSmithKline,[9][10] then served as chief immunology officer at Kintai Therapeutics. In December 2020, Tak became president and CEO of Candel Therapeutics.[11][12]

Publications[]

Tak has an h-index of 136 according to Google Scholar.[13] His publications include:

  • Aletaha, Daniel; Neogi, Tuhina; Silman, Alan J.; Funovits, Julia; Tak, Paul P.; et al. (September 2010). "2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative". Arthritis & Rheumatism. 62 (9): 2569–2581. doi:10.1002/art.27584. PMID 20872595.
  • Tak, Paul-Peter; Firestein, Gary S. (January 2001). "NF-κB: a key role in inflammatory diseases". The Journal of Clinical Investigation. 107 (1): 7–11. doi:10.1172/JCI11830. ISSN 0021-9738. PMC 198552. PMID 11134171.
  • Tracey, Daniel; Klareskog, Lars; Sasso, Eric H.; Salfeld, Jochen G.; Tak, Paul P. (1 February 2008). "Tumor necrosis factor antagonist mechanisms of action: A comprehensive review". Pharmacology & Therapeutics. 117 (2): 244–279. doi:10.1016/j.pharmthera.2007.10.001. ISSN 0163-7258. PMID 18155297.
  • Okada, Yukinori; Wu, Di; Trynka, Gosia; Raj, Towfique; Tak, Paul P.; et al. (20 February 2014). "Genetics of rheumatoid arthritis contributes to biology and drug discovery". Nature. 506 (7488): 376–381. doi:10.1038/nature12873. ISSN 0028-0836. PMC 3944098. PMID 24390342.

References[]

  1. ^ a b "Paul Peter Tak | Precision Medicine". www.terrapinn.com. 17 May 2018. Retrieved 3 August 2018.
  2. ^ "Paul-Peter Tak - profile". Bloomberg.com. Retrieved 3 August 2018.
  3. ^ Tak, Professor Paul-Peter (December 2017). "Interview with Paul-Peter Tak: Stimulating the vagus nerve to treat rheumatoid arthritis". Bioelectronics in Medicine. 1 (1): 17–20. doi:10.2217/bem-2017-0012. ISSN 2059-1500.
  4. ^ "ACR Annual Meeting" (PDF). American College of Rheumatology. November 2012. Retrieved 7 August 2018.
  5. ^ "Professor Paul-Peter Tak | The Academy of Medical Sciences". acmedsci.ac.uk. Retrieved 8 August 2018.
  6. ^ "Mednet Topartsen 2010". Mednet (in Dutch). 4 (1): 6–15. January 2011. doi:10.1007/s12462-011-0006-8. ISSN 1568-7716. S2CID 195312669.
  7. ^ "Prizes". NVR Nederlandse Vereniging voor Reumatologie (in Dutch). Retrieved 10 August 2018.
  8. ^ Expertscape. "Expertscape Ranks World's Top Doctors and Hospitals in Rheumatoid Arthritis". PRLog. Retrieved 10 August 2018.
  9. ^ Eaton, Elizabeth. "Tak leaves GSK to join Flagship". Biocentury.com. Retrieved 31 January 2019.
  10. ^ "GlaxoSmithKline Scientist Steps Down to Join Flagship Pioneering". Business Leader. 7 February 2019. Retrieved 8 February 2019.
  11. ^ "Ex-GSK immunology chief takes over oncolytic virus biotech Candel as it ramps up its pipeline". FierceBiotech. 9 December 2020. Retrieved 17 March 2021.
  12. ^ Al Idrus, Amirah. "Ex-GSK Shingrix chief Pfefer lands at Flagship as its 2nd CEO-Partner". FierceBiotech. Retrieved 30 October 2020.{{cite web}}: CS1 maint: url-status (link)
  13. ^ "Paul Peter Tak". Google Scholar. Retrieved 27 September 2021.
Retrieved from ""